Proposed FDA Rule Could Bring Failure-To-Warn Liability
A rule proposed by the U.S. Food and Drug Administration in early November could increase generic drug manufacturers' exposure to legal liability. Specifically, the FDA is proposing to amend 21 C.F.R....To view the full article, register now.
Already a subscriber? Click here to view full article